SBH
COGT icon

Segall Bryant & Hamill’s Cogent Biosciences COGT Stock Holding History

Segall Bryant & Hamill’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3M Buy
+421,207
New +$14.7M 0.19% 188

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Segall Bryant & Hamill's COGT Position: Q2 2026 in Review

Segall Bryant & Hamill opened a new position in Cogent Biosciences (COGT) in Q2 2026: 421,207 shares worth $16.3M. The stake represents 0.19% of the portfolio and ranks #188 among its holdings.

322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Segall Bryant & Hamill held 421,207 shares of Cogent Biosciences worth $16.3M as of Q2 2026.
  • Cogent Biosciences was a new Segall Bryant & Hamill position in Q2 2026.
  • Cogent Biosciences made up 0.19% of Segall Bryant & Hamill's portfolio in Q2 2026, its #188 holding.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.